Canagliflozin for the treatment of adults with Type 2 diabetes
Mostra/ Apri
Data
2013Autore
Aschner Montoya, PabloAutore/i aziendale
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología
Tipo
Artículo de revista
ISSN
1758-1907
COAR
Artículo de revisiónCondividi questo record
Citación
Metadata
Mostra tutti i dati dell'item
Documenti PDF
Astratto
Canagliflozin is a competitive, reversible and potent inhibitor of SGLT2 that lowers the renal threshold for glucose and consequently increases urinary glucose excretion in people with Type 2 diabetes with a blood glucose level above 70–90 mg/dl. Its oral administration in daily doses of 100 and 300 mg in onotherapy, dual therapy or triple therapy including insulin produces a mean HbA1c reduction of 0.7 and 0.85%, respectively, when compared with placebo, a similar reduction to sitagliptin and glimepiride. There is also a modest reduction in weight with both doses. The main adverse effects are genital fungal infections, particularly in women, and, less frequently, urinary tract infections.
comunità
AdultosLink alla risorsa
https://www.openaccessjournals.com/abstract/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-8095.htmlEditoriale
Diabetes Management; Volumen 3 Número 4 , Páginas 343 - 350 (2013)
Google Analytics Statistics
Collections
- Artículos [56]